



Attorney Docket No.: 6258.200-US

COPY OF PAPERS
ORIGINALLY FILED

PATENT

1614
HB
7/8/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lau et al

Serial No.: 09/996,023

Group Art Unit: 1614

Filed: November 16, 2001

Examiner: To be assigned

Confirmation No: 2060

For: Glucagon Antagonists/Inverse Agonists

RECEIVED

JUN 12 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Supplemental Information Disclosure Statement
2. Form PTO-1449
3. Copy of Reference (1 Total)

is being deposited with the United States Postal Service as first class mail in an envelope
addressed to:

Commissioner for Patents
Washington, DC 20231

on May 29, 2002.

Sylvia Gonzalez
(name of person mailing paper)
Sylvia Gonzalez
(signature of person mailing paper)



Attorney Docket No.: 6258.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lau et al

Application No.: 09/996,023

Group Art Unit: 1614

Filed: November 16, 2001

Examiner: To be assigned

Confirmation No.: 2060

RECEIVED

JUN 12 2002

TECH CENTER 1600/2901

For: Glucagon Antagonists/Inverse Agonists

COPY OF PAPERS
ORIGINALLY FILED

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The reference is listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the reference is also enclosed.

The references are as follows:

1. WO 00/69810

It is respectfully requested that this reference be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed before the mailing date of a first Office action on the merits. Therefore, no fee is due.

Respectfully submitted,

Date: May 29, 2002

Richard W. Bork
Richard W. Bork, Reg. No. 36,459
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE